Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC) represents a significant health challenge, often impacting critical functions like breathing, eating, and speaking. This comprehensive guide provides an in-depth overview for students, covering its history, causes, diagnosis, treatment, and management strategies.

Understanding Head and Neck Squamous Cell Carcinoma: A Historical Journey

The evolution of treating head and neck squamous cell carcinoma is a testament to medical progress. Before general anesthesia, most cancer operations were limited to visible external growths. Early treatments, dating back to the Ebers Papyrus (15th century BC), involved topical remedies for chronic gum ulcers, while Hippocrates (460 BC) described tumors as "carcinoma" due to their claw-like extensions and cautioned against deeply invasive surgery.

Medieval Arab physicians like Avicenna and Albucasis performed lip excisions, though defects healed by secondary intention. The Renaissance saw a shift from humoral theories to anatomical studies, and the 16th century noted an increase in oral cancers, possibly due to tobacco. Early surgical methods included excision, cautery, and mass ligation to manage bleeding, remaining mainstays until general anesthesia.

The advent of general anesthesia in 1846 by William Thomas Green Morton, followed by surgical removal of a submandibular gland tumor by John Collins Warren, revolutionized surgery. This allowed for planned, extensive operations. Karl Billroth performed the first total laryngectomy in 1873, though initial mortality rates were high. Gluck and Sorensen later improved laryngectomy techniques, while surgeons like Billroth, Von Langenbeck, and Trotter developed access techniques like lip splitting and mandibulotomy.

George Crile of Cleveland established the locoregional approach in 1906 with his description of radical neck dissection, significantly improving 3-year survival rates. Around the same time, the Curies discovered radium, leading to early radiotherapy applications. Coutard described fractionation in 1919, dividing radiation doses to reduce toxicity. From 1910–1940, radiotherapy became the treatment of choice for many pharyngeal and laryngeal tumors due to high surgical complication rates.

Post-WWII, advancements in blood transfusion and antibiotics made major surgeries more viable. Grant Ward and colleagues at Johns Hopkins extended Crile's principles to composite resections, involving the mandible and neck. This became known as the "Commando procedure." In the 1960s, Ballantyne and Bocca refined radical neck dissection to preserve function, leading to the concept of selective neck dissection in the 1970s and 1980s. The logical step of combining surgery and radiotherapy (adjuvant therapy) emerged to improve cure rates and reduce surgical radicality.

Chemotherapy, particularly methotrexate, showed tumoricidal effects in the 1950s. Induction chemotherapy with Cisplatin and 5FU later demonstrated comparable disease-free survival to laryngectomy, promoting organ preservation. The 1960s also saw the development of combined intracranial and extracranial approaches for skull base tumors, and endoscopic surgery with lasers expanded in the recent era for early-stage laryngeal lesions.

Head and Neck Squamous Cell Carcinoma: Basic Science and Epidemiology

HNSCC is a classic example of chemical carcinogenesis, often initiated by tobacco toxins and promoted by alcohol intake. Polycyclic aromatic hydrocarbons (e.g., benzopyrene) in tobacco smoke damage mucosal cells, especially where saliva pools. Alcohol acts as a co-factor, dramatically increasing risk when combined with tobacco.

Worldwide, especially in developing countries, HNSCC is a significant public health issue. While decreasing in the US due to reduced tobacco use, global incidence and mortality are projected to rise. Other risk factors include:

• Promoting Agents: Submucous fibrosis (South Asia, with betel nut chewing), iron deficiency anemia (Plummer–Vinson syndrome), Vitamin A deficiency.
• Occupational Exposures: Nickel, radium, mustard gas, wood dust.
• Viral Infections: Epstein–Barr virus (nasopharyngeal carcinoma) and Human Papillomavirus (HPV) types 16, 18, 31 (tonsil and base of tongue cancers). HPV-associated tumors generally have a better survival rate.
• Genetic Alterations: Amplification of oncogenes (e.g., cyclin D1), mutations in the TP53 gene, amplification of CDKN2A/p16 gene, and increased EGFR expression. Decreased DNA repair capacity in mucosal cells is a common pathway.

The "field effect" concept suggests that the entire upper aerodigestive tract mucosa is at risk for cancer development. This explains the high incidence of synchronous (5–7%) and secondary primary cancers (20–30%). HNSCC typically progresses locally, then to regional lymph nodes, and finally to distant metastases.

Recognizing Head and Neck Cancer Symptoms and Diagnosis

Unfortunately, many patients with head and neck cancer present with advanced disease. A mass in the neck, representing regional metastases, is the presenting symptom in 25% of oral/oropharyngeal and 50% of nasopharyngeal cancers.

• Neck Masses: The location can predict the primary site:
• Level I (submandibular/submental): Lip, anterior tongue, floor of mouth.
• Level II (jugulodigastric/upper jugular): Oral cavity, oropharynx, nasopharynx.
• Level III (mid-jugular): Oropharynx, hypopharynx, lateral tongue.
• Level IV (lower jugular): Thyroid, visceral, breast primaries.
• Level V (posterior triangle): Scalp, nasopharynx, parotid.

Other less specific but crucial symptoms include sore throat, hoarseness, stridor, dysphagia, and unilateral ear pain. A thorough examination involves direct inspection, palpation, laryngeal mirrors, or a flexible nasolaryngoscope. Signs may include red/white patches, ulcerations, masses, poor dentition, tongue edema, nasal obstruction, proptosis, or unilateral ear effusion. Palpation defines masses or pain.

Imaging studies are critical:

• CT: Useful for bone involvement.
• MRI: Superior for soft tissue tumors, nodal involvement, perineural spread, and bony invasion.
• Chest X-ray/CT: Essential due to high incidence of lung metastases and second primary cancers.
• PET-CT: May be useful for later-stage locoregional disease or suspected distant metastases, though sensitivity is greater than specificity.

Suspicious neck masses are evaluated by aspiration cytology. Nutritional status, hemoglobin levels, and mental health (depression is 10x more common) should also be assessed and addressed before treatment.

Staging Head and Neck Squamous Cell Carcinoma: The TNM System

The American Joint Committee for Cancer (AJCC) and Union Internationale Contre le Cancer (UICC) use the TNM (tumor, nodal metastasis, systemic metastases) system to stage head and neck cancers. This system guides prognosis, treatment planning, and comparison of therapeutic effectiveness.

• T-stage: Describes primary tumor size and adjacent structure involvement.
• N-status: Describes size, number, and laterality of cervical lymph nodes.
• M-status: Indicates presence or absence of distant metastases.

Accurate staging is crucial but can be challenging due to complex anatomy and tumor biology variability. Future research aims to combine TNM with molecular markers (e.g., EGFR, Cyclin D1, HPV DNA, p53 gene) to predict tumor behavior and guide targeted therapies more effectively.

Therapeutic Choices for Head and Neck Squamous Cell Carcinoma Treatment

Treatment decisions are highly individualized, based on tumor site, size, adjacent structure involvement, and patient factors. Preserving critical functions like respiration and alimentation is paramount.

• Surgical Oncology Principles: Remove the primary tumor with a margin of normal tissue and perform a neck dissection (preferably en bloc) to remove metastatic or high-risk lymph nodes.
• Radiation Oncology Principles: Deliver a lethal dose to the primary tumor and a lower dose to the surrounding area and draining lymph nodes.

For early-stage (T1, T2) tumors without nodal metastases, surgery or radiation offer relatively equivalent disease-free survival. For Stage III and IV disease with cervical nodal metastases, surgery followed by adjuvant radiotherapy is the most appropriate therapy.

• Radiation Therapy: Often preferred for T1/T2N0 cancers of the larynx, hypopharynx, and nasopharynx to preserve function and avoid surgical complications like xerostomia or osteoradionecrosis.
• Surgery: More common for T1/T2N0 tumors of the oropharynx, oral cavity, and paranasal sinuses where it may cause less dysfunction.

The desire to preserve function has spurred interest in organ preservation protocols using induction chemotherapy and definitive radiotherapy, particularly for laryngeal, hypopharyngeal, and oropharyngeal cancers. Salvage surgery can be performed if initial combined therapy is unsuccessful.

Surgical Access and Site-Specific Management

Adequate access and visualization are crucial for successful tumor resection. Surgeons use various techniques to expose tightly packed structures while preserving neurovascular integrity. Common access approaches include:

• Lip Splitting (Labiotomy): Midline incisions for symmetry and to avoid vascular issues.
• Mandibulotomy: Midline or mesial to the mental nerve to preserve sensation, providing wide access to the posterior oral cavity, tongue base, and pharynx.
• Caldwell–Luc Incision: For unilateral maxilla access, extendable to a facial degloving incision for total midface exposure.
• Weber–Ferguson Incision: For unilateral exposure to the nose, sinuses, palate, and orbit.
• Retrosymphysial Transverse Incision: From the neck to enter the oral cavity from below.

Lip Cancer (Squamous Cell Carcinoma of the Lip)

Over 90% of lip malignancies are SCC, primarily affecting the lower lip. Etiologies include tobacco, solar exposure, and viral infections. Larger, infiltrative lesions may cause paresthesia due to mental nerve involvement. Preoperative evaluation includes a complete head and neck exam and imaging for T1 or invasive lesions. Surgery is the primary treatment, with definitive radiation reserved for patients unable to tolerate surgery.

• Resection: Smaller lesions (<1/2 lower lip) can be primarily repaired (wedge or “V” excision) with 5mm–1cm margins. Larger resections require adjacent tissue flaps (e.g., Karapandzic, fan flaps) or free tissue transfers.
• Cervical Metastasis: Less common (2–12%), but higher risk for upper lip/commissure tumors and those >2cm. Comprehensive neck dissection is indicated for metastatic disease.

Buccal Mucosa Cancer

Rare in the US, common in Central and South Asia due to chewing tobacco/betel nut. Deeper invasion into muscle or Stensen’s duct correlates with decreased survival.

• Treatment: Smaller tumors resected transorally with primary closure or skin grafts. Larger lesions require addressing bone (marginal/segmental mandibulectomy, partial maxillectomy) and reconstruction with fasciocutaneous free tissue transfer.
• Regional Nodal Management: Occult nodal metastasis rate ~26%. Elective selective neck dissection should be considered for N0 patients with T>T1 tumors. Adjuvant radiation for >1 positive node, extracapsular extension, or close margins.
• Complication: Severe trismus is a significant problem, requiring aggressive physical therapy.

Floor of Mouth Cancer

Often difficult to evaluate due to proximity to mandible and dentition. High risk of regional metastasis (21% in Stage I, 62% in Stage II).

• Treatment: Smaller lesions transoral resection, healed by secondary intention or skin graft. Larger lesions require mandibulotomy for access, marginal resections, and thin, supple fasciocutaneous flaps (e.g., radial forearm flap) for reconstruction.
• Nerve Preservation: Lingual and hypoglossal nerves are at risk during resection.
• Regional Nodal Management: 30% present with positive nodes. Elective supraomohyoid neck dissection for deeply infiltrated lesions (>3mm) or lesions crossing the midline. Adjuvant radiotherapy for positive nodes, extranodal extension, or close margins.

Alveolar Ridge and Retromolar Trigone Cancer

Found on the posterior mandibular alveolar ridge or retromolar trigone. Early bone involvement is common due to mucosal approximation to bone. Extension into masticator space indicates poor prognosis. Cervical metastasis rate ~26%.

• Treatment: Smaller lesions transoral resection, secondary healing or skin graft. Larger tumors require mandible management (marginal or segmental mandibulectomy) or partial maxillectomy. Defects closed with local flaps or dental appliances.
• Survival: 5-year survival 50–65%, markedly decreased with cervical metastases.
• Adjuvant Therapy: Indicated for close/positive margins, perineural/perivascular invasion, multiple positive nodes, or extracapsular spread.

Hard Palate Cancer

Rare in the US (0.5% of oral cancers), but common in India (40%). Usually well-differentiated with a low occult cervical metastatic rate (10–25% positive nodes, Level I/II most common).

• Management: Smaller tumors resected periorally, defect covered with a stent and healed by secondary intention. Bone involvement requires resection with adequate margins. Reconstruction with local flap and/or obturator/prosthesis. Larger invasive tumors require maxillectomy. Regional metastatic disease addressed with neck dissection.
• Adjuvant Therapy: For advanced disease, close margins, perineural/perivascular invasion, or extranodal extension.
• Prognosis: Lesions >3cm have significantly reduced 5-year cure rates.

Oral Tongue Cancer

Exceeds all other intraoral sites, most commonly on the lateral border of the middle third. Anterior/middle third lesions are exophytic/ulcerative, while posterior third are deeper, infiltrative. Often arises in leukoplakia/erythroplasia. Regional metastasis is frequent, especially for middle and base of tongue lesions.

• Management: Majority with resection (at least 1cm margins). T1/T2 lesions of anterior/middle third with wedge excision. Larger lesions crossing midline require careful preservation of lingual artery, lingual, and hypoglossal nerves. Posterior lesions require mandibulotomy for access, defects reconstructed with skin grafts or fasciocutaneous free tissue transfer.
• Nodal Management: High risk of occult nodal disease (20–40%, Level I–III). Elective supraomohyoid neck dissection is a good diagnostic and therapeutic modality for N0 necks at risk. Patients with positive nodes need adjuvant radiotherapy.
• Survival: 5-year disease-free survival 80–90% for T1/T2, 54% for Stage III, 34% for Stage IV.

Oropharyngeal Cancer

Involves soft palate, tonsils, base of tongue, posterior pharyngeal wall, and vallecula. Less than 1% of malignancies. Smoking and alcohol are main etiologies, but HPV infection is a rising cause in young non-smokers/non-drinkers. Tumors tend to be poorly differentiated and exhibit early regional metastases.

• Base of Tongue: 25–30% of lingual SCCs, often T2–T3 at presentation, with high rates of clinically positive regional nodes (20–30% bilateral/contralateral).
• Treatment: Single modality (surgery or radiation) for Stage I/II. Definitive radiation therapy often selected due to high occult metastasis rates, requiring elective treatment of N0 necks. Midline lesions warrant bilateral neck treatment.
• Advanced Stage Management: Multidisciplinary, multimodality therapy with chemoradiation protocols is common. Options include surgery + adjuvant radiation, definitive concurrent chemoradiation, surgery + adjuvant chemoradiation, or induction chemotherapy + concurrent/sequential chemoradiation. Organ preservation protocols aim to decrease morbidity and improve quality of life. There's no significant difference in 3-year disease-free survival between surgery + adjuvant radiation and chemoradiation.

Neck Dissection Techniques

Nodal metastasis profoundly negatively impacts survival. The risk of occult metastasis is high for most oral cavity cancers, directly related to tumor thickness.

Supraomohyoid Neck Dissection

Effective for diagnostic staging and therapeutic management of the clinically N0 neck in patients at risk for occult metastasis (Levels I, II, III). Incision in a natural skin crease from mastoid to midline, two finger-breadths below the mandible angle. Subplatysmal flaps raised, preserving greater auricular and marginal mandibular nerves. Dissection proceeds through Levels I, II, and III, carefully identifying and preserving lingual and hypoglossal nerves, and managing submandibular gland structures.

Modified Radical Neck Dissection

Indicated for clinical evidence of cervical nodal metastasis, including Levels I–V, often sparing the sternocleidomastoid muscle (SCM), internal jugular vein (IJ), and spinal accessory nerve (SAN). Begins in Level V, carefully identifying and preserving the SAN. Dissection proceeds through all levels, delivering tissue in continuity, with meticulous hemostasis and careful closure over drains.

Major Problems: Avoidance and Management in Head and Neck Squamous Cell Carcinoma

Complications range from oncologic failure to wound issues and sequelae of radiotherapy. Careful planning, meticulous technique, and adherence to oncologic principles minimize these.

• Local Recurrence: Return of tumor at the original resection site, highest in the first 2–3 years. Often due to incomplete initial resection. Prevention relies on achieving 1cm margins, confirmed by intraoperative frozen sections. Management involves re-resection.
• Regional Recurrence: Malignant spread to regional lymph nodes after initial disease resection. Avoidance achieved by appropriate patient selection for neck dissection based on risk (e.g., >2–3mm invasion warrants staging neck dissection). Suspicious nodes biopsied preoperatively.
• Wound Infection/Dehiscence: Can lead to salivary fistulae. Prevented by meticulous, watertight, multi-layered closure of the incision. Oral incisions are prone to infection.
• Osteoradionecrosis (ORN): Necrosis of bone in an irradiated field, often triggered by local trauma (e.g., tooth extraction). Most common in the mandible. Prevention includes rounding bone cuts, covering bone with healthy soft tissue, and thorough dental evaluation/extractions prior to radiation. Management involves hyperbaric oxygen, limited sequestrectomy for early stages, or radical debridement and free vascularized bone flaps for advanced disease.

Life After Treatment: Post-Treatment Surveillance for HNSCC Patients

Surveillance is critical for detecting recurrence and, importantly, identifying second primary cancers, which are the most common cause of failure after 36 months. Regular follow-up schedule:

• Year 1: Every 6–8 weeks.
• Year 2: Every 8–10 weeks.
• Year 3: Every 10–12 weeks.
• Year 4+: Twice yearly.
• After 5 years: Annual exams, with heightened suspicion for second primary tumors.

Each appointment includes a complete history (swallowing, pain, trismus, hoarseness, weight loss) and physical examination. Imaging (CT, MRI) is more sensitive than physical exam alone for local/regional recurrence, though CT radiation exposure should be considered. PET/CT can detect recurrence/metastases but should be used cautiously in the early postoperative period due to inflammation.

Dental Follow-up: HNSCC patients need dental exams/cleanings every 6 months. Radiation changes salivary function, increasing dental decay risk. Patients require daily fluoride therapy for life to prevent radiation caries.

FAQ: Common Questions about Head and Neck Squamous Cell Carcinoma

What are the main causes of Head and Neck Squamous Cell Carcinoma?

The primary causes are tobacco use and alcohol consumption. Other factors include Human Papillomavirus (HPV) infection, certain occupational exposures, and genetic predispositions, as outlined in the epidemiology section of this article.

How is Head and Neck Squamous Cell Carcinoma diagnosed and staged?

Diagnosis involves clinical examination, palpation, endoscopy, and imaging studies like CT, MRI, and PET-CT. Staging uses the TNM system (Tumor, Nodal Metastasis, Distant Metastasis) to classify the extent of the disease, which then guides treatment decisions.

What are the main treatment options for HNSCC?

Treatment often involves a combination of surgery, radiation therapy, and chemotherapy. The specific approach depends on the tumor's stage, location, and the patient's overall health. For early stages, surgery or radiation may be sufficient, while advanced stages typically require combined modality therapy like surgery followed by adjuvant radiation.

What is osteoradionecrosis and how can it be avoided?

Osteoradionecrosis (ORN) is the necrosis of bone in an area that has been treated with radiation. It most commonly affects the mandible. Avoiding ORN involves careful surgical planning, ensuring soft tissue coverage over bone, and prophylactic dental care, including extractions of diseased teeth before radiation, and daily fluoride therapy for life.

Why is post-treatment surveillance so important for HNSCC patients?

Post-treatment surveillance is crucial for early detection of any local or regional recurrence of the original cancer. Even more importantly, it helps identify the development of new, second primary cancers, which are a common cause of long-term treatment failure in this patient population due to the widespread "field effect" of carcinogens.